Immunotech Biopharm Balance Sheet Health
Financial Health criteria checks 1/6
Immunotech Biopharm has a total shareholder equity of CN¥78.3M and total debt of CN¥285.8M, which brings its debt-to-equity ratio to 364.8%. Its total assets and total liabilities are CN¥719.7M and CN¥641.4M respectively.
Key information
364.8%
Debt to equity ratio
CN¥285.79m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥145.31m |
| Equity | CN¥78.33m |
| Total liabilities | CN¥641.39m |
| Total assets | CN¥719.72m |
Financial Position Analysis
Short Term Liabilities: 6978's short term assets (CN¥180.8M) do not cover its short term liabilities (CN¥478.2M).
Long Term Liabilities: 6978's short term assets (CN¥180.8M) exceed its long term liabilities (CN¥163.2M).
Debt to Equity History and Analysis
Debt Level: 6978's net debt to equity ratio (179.3%) is considered high.
Reducing Debt: 6978's debt to equity ratio has increased from 0% to 364.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6978 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 6978 has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.6% each year.